A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN

被引：0
|
作者：
Darba, J. [1 ]
Restovic, G. [2 ]
Ramirez de Arellano, A. [3 ]
机构：
[1] Univ Barcelona, Barcelona, Spain
[2] BCN Hlth Econ & Outcomes Res SL, Barcelona, Spain
[3] Roche Farma SA, Madrid, Spain
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66563-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A467 / A467
页数：1
相关论文
共 50 条
  • [1] Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer
    Garrison, L.
    Cassidy, J.
    Saleh, M.
    Lee, F.
    Mena, R.
    Fuloria, J.
    Chang, V.
    Ervin, T.
    Stella, P.
    Saltz, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Cost-analysis of xelox vs. folfox-4 ± bevacizumab (BEV) in metastatic colorectal cancer (MCRC) in an Italian hospital setting
    Garrison, L. P.
    Giuliani, G.
    Ducournau, P.
    Cirrincione, A.
    VALUE IN HEALTH, 2007, 10 (06) : A334 - A334
  • [3] Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer
    Teitelbaum, Ursina R.
    Haller, Daniel G.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (05) : 250 - 251
  • [4] Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer
    Ursina R. Teitelbaum
    Daniel G. Haller
    Nature Reviews Clinical Oncology, 2009, 6 : 250 - 251
  • [5] A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
    Grothey, Axel
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (01): : 10 - 11
  • [6] A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
    Axel Grothey
    Nature Clinical Practice Oncology, 2009, 6 : 10 - 11
  • [7] Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan
    Shiroiwa, Takeru
    Fukuda, Takashi
    Tsutani, Kiichiro
    CLINICAL THERAPEUTICS, 2007, 29 (10) : 2256 - 2267
  • [8] Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
    Andrea Queiróz Ungari
    Leonardo Régis Leira Pereira
    Altacílio Aparecido Nunes
    Fernanda Maris Peria
    BMC Cancer, 17
  • [9] Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
    Ungari, Andrea Queiroz
    Leira Pereira, Leonardo Regis
    Nunes, Altacilio Aparecido
    Peria, Fernanda Maris
    BMC CANCER, 2017, 17
  • [10] THE COST EFFECTIVENESS ANALYSIS OF CAPDX VERSUS FOLFOX-4 REGIMENS WITH OR WITHOUT BEVACIZUMAB IN THE FIRST LINE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN HONG KONG
    Lee, V. W.
    Cheng, F.
    Wan, K. P.
    Chik, J.
    Chan, D.
    Cheng, A.
    Wong, K. H.
    VALUE IN HEALTH, 2017, 20 (05) : A109 - A109
12345